Posted by Michael Wonder on 09 May 2024
ICER releases draft evidence report on treatment for anaemia in myelodysplastic syndrome
9 May 2024 - Public comment period now open until 10 June 2024; requests to make oral comment during public meeting also being accepted.
The ICER today released a draft evidence report assessing the comparative clinical effectiveness and value of imetelstat (Geron Corporation) for the treatment of anaemia in myelodysplastic syndrome.
